
    
      This study will be a Phase 2, double-blind, randomized, placebo-controlled study in up to 30
      participants. Participants will be randomized in a 2:1 ratio and will receive a once-weekly
      subcutaneous (SC) treatment with either IONIS-AGT-LRx or placebo, with an additional loading
      dose administered on Study Day 3. The treatment will last for 8 weeks and the post-treatment
      period will last for 13 weeks.
    
  